Both GLP-1 and GIP are insulinotropic at basal and postprandial glucose levels and contribute nearly equally to the incretin effect of a meal in healthy subjects

Kolligs, 1995, Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9–39) amide, Diabetes, 44, 16, 10.2337/diab.44.1.16 Tseng, 1996, Postprandial stimulation of insulin release by glucose-dependent insulinotropic polypeptide (GIP). Effect of a specific glucose-dependent insulinotropic polypeptide receptor antagonist in the rat, J. Clin. Invest., 98, 2440, 10.1172/JCI119060 Wang, 1995, Glucagon-like peptide-1 is a physiological incretin in rat, J. Clin. Invest., 95, 417, 10.1172/JCI117671 Nauck, 1986, Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses, J. Clin. Endocrinol. Metab., 63, 492, 10.1210/jcem-63-2-492 Kreymann, 1987, Glucagon-like peptide-1 7–36: a physiological incretin in man, Lancet, 2, 1300, 10.1016/S0140-6736(87)91194-9 Edwards, 1999, Glucagon-like peptide 1 has a physiological role in the control of postprandial glucose in humans—studies with the antagonist exendin 9–39, Diabetes, 48, 86, 10.2337/diabetes.48.1.86 Scrocchi, 1996, Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene, Nat. Med., 2, 1254, 10.1038/nm1196-1254 Meier, 2001, Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes, Diabetes, 50, 2497, 10.2337/diabetes.50.11.2497 Nauck, 1993, Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations, J. Clin. Endocrinol. Metab., 76, 912 Miyawaki, 1999, Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice, Proc. Natl. Acad. Sci. U. S. A., 96, 14843, 10.1073/pnas.96.26.14843 Jia, 1995, Effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-I-(7–36) on insulin-secretion, Am. J. Physiol.: Endocrinol. Metab., 31, E645 Toft-Nielsen, 1998, Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia, Diabetologia, 41, 1180, 10.1007/s001250051049 Nauck, 1989, Insulinotropic properties of synthetic human gastric inhibitory polypeptide in man: interactions with glucose, phenylalanine, and cholecystokinin-8, J. Clin. Endocrinol. Metab., 69, 654, 10.1210/jcem-69-3-654 Deacon, 2000, Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide, J. Clin. Endocrinol. Metab., 85, 3575 Orskov, 1994, Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans, Diabetes, 43, 535, 10.2337/diab.43.4.535 Vilsboll, 2001, Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients, Diabetes, 50, 609, 10.2337/diabetes.50.3.609 Gutniak, 1996, Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet, Diabetes Care, 19, 843, 10.2337/diacare.19.8.843 Krarup, 1983, Diminished immunoreactive gastric inhibitory polypeptide response to a meal in newly diagnosed type I (insulin-dependent) diabetics, J. Clin. Endocrinol. Metab., 56, 1306, 10.1210/jcem-56-6-1306 Krarup, 1984, The heterogeneity of gastric inhibitory polypeptide in porcine and human gastrointestinal mucosa evaluated with five different antisera, Regul. Pept., 9, 35, 10.1016/0167-0115(84)90005-3 Orskov, 1991, Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine, J. Clin. Invest., 87, 415, 10.1172/JCI115012 Mccullough, 1983, Effect of graded intraduodenal glucose infusions on the release and physiological action of gastric-inhibitory polypeptide, J. Clin. Endocrinol. Metab., 56, 234, 10.1210/jcem-56-2-234 Pederson, 1976, Insulinotropic action of gastric inhibitory polypeptide in perfused isolated rat pancreas, Endocrinology, 99, 780, 10.1210/endo-99-3-780 Fehmann, 1995, Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide, Endocr. Rev., 16, 390, 10.1210/edrv-16-3-390 Hvidberg, 1994, Effect of glucagon-like peptide-1 (proglucagon 78–107 amide) on hepatic glucose production in healthy man, Metabolism, 43, 104, 10.1016/0026-0495(94)90164-3 Orskov, 1996, Secretion of the incretin hormones glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin secretion in normal man throughout the day, Scand. J. Gastroenterol., 31, 665, 10.3109/00365529609009147 Muller, 1970, Abnormal alpha-cell function in diabetes—response to carbohydrate and protein ingestion, N. Engl. J. Med., 283, 109, 10.1056/NEJM197007162830301 Ohneda, 1969, Control of pancreatic glucagon secretion by glucose, Diabetes, 18, 1, 10.2337/diab.18.1.1